
|Articles|January 6, 2005
FDA approves new oral agent for overactive bladder
The FDA has approved extended-release darifenacin (Enablex, 7.5 mg and 15 mg) for the treatment of overactive bladder.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Study suggests potential diuretic effect with nadofaragene firadenovec
2
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
3
Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











